[8] reported that among hormone receptor (HR)‐positive breast cancer patients, HER2‐low patients had a significantly lower pathological complete response (pCR) rate after neoadjuvant chemotherapy than HER2‐negative patients did. Here, NR4A1 is linked to breast cancer.